Eikon Therapeutics, Inc. Common Stock (NASDAQ: EIKN) is a Healthcare company (Biotechnology) with a market capitalization of $279M. The Maz Rating grades it against the other companies in its sector.
Eikon Therapeutics, Inc. Common Stock's current Maz Rating and its five factor grades are for members: log in to see them.
At $5.15, Eikon Therapeutics, Inc. Common Stock trades at 0.7x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -258.1%, return on invested capital of -54.6% and a free cash flow yield of -96.0%. On the balance sheet: a debt-to-equity ratio of 0.65 and a current ratio of 7.21. Over the past 52 weeks the share price ranged from $4.95 to $17.40, with a beta of 0.94.
Eikon Therapeutics, Inc. Common Stock does not currently pay a dividend.
1 Wall Street analyst rating covers the stock: 1 Sell, for a Sell consensus. This is the sell side's view, separate from the Maz Rating.
Eikon Therapeutics, Inc. is a clinical biopharmaceutical company, established in 2019 and headquartered in Millbrae, California, operating within the United States. The company is dedicated to developing groundbreaking medicines to address significant unmet medical needs. It utilizes a proprietary platform capable of precisely characterizing protein interactions inside living cells. Eikon's drug pipeline includes EIK1001, a systemically delivered TLR 7/8 dual-agonist designed to activate both innate and adaptive anti-cancer immune responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors for ovarian, breast, prostate, and pancreatic cancers. Notably, EIK1004 is brain-penetrant, offering a therapeutic approach for brain metastases and primary brain malignancies. Additionally, EIK1005 is a potent WRN helicase inhibitor and anti-tumor agent aimed at MSI-high tumors, alongside EIK1006.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Eikon Therapeutics, Inc. Common Stock (EIKN) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 103.3% / 30% · Interest income / Revenue 448600000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 103.3% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 448600000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 103.3% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 448600000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.65% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 62.8% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 448600000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 65.4% / 33.33% · (Cash+Recv) / Total Assets 65.4% / 33.33% · Interest income / Revenue 448600000.0% / 5% | Fail |
No. As of September 2026, Eikon Therapeutics, Inc. Common Stock (EIKN) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Eikon Therapeutics, Inc. Common Stock is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 448600000.0% of each dividend: Eikon Therapeutics, Inc. Common Stock's interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.